- Home
- EU vs SRZN Comparison
EU vs SRZN Comparison
Compare EU & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | SRZN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 271.6M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | EU | SRZN |
|---|---|---|
| Price | $1.24 | $25.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 2.9M | 267.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $43,155,000.00 | N/A |
| Revenue This Year | $212.11 | $75.35 |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | $41.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $9.66 |
| 52 Week High | $4.19 | $35.00 |
Technical Indicators
Market Signals| Indicator | EU | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 47.35 |
| Support Level | N/A | $20.26 |
| Resistance Level | $1.79 | $24.13 |
| Average True Range (ATR) | 0.07 | 1.89 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 47.83 | 66.67 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).